🏛️ Verified NIH Record • Updated 2025-12-02
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) (NCT03897881)
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: ModernaTX, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Who can join: Review the eligibility criteria below.
Location: University of Arizona — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- University of Arizona — Tucson, Arizona
- California Pacific Medical Center Research Institute -CPMCRI — San Francisco, California
- Angeles Clinic and Research Institute — Santa Monica, California
- University of Colorado Cancer Center — Aurora, Colorado
- Smilow Cancer Center at Yale New Haven Hospital — New Haven, Connecticut
- Lombardi Cancer Center — Washington D.C., District of Columbia
- Orlando Health UF Health Cancer Center — Orlando, Florida
- Northside Hospital — Atlanta, Georgia
- UPMC Hillman Cancer Center — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- NYU Langone Medical Center — New York, New York
- Providence Cancer Institute — Portland, Oregon
- Sarah Cannon Cancer Center — Nashville, Tennessee
- Texas Oncology PA — Dallas, Texas
- Melanoma Institute Australia — North Sydney, New South Wales
- Westmead Hospital — Westmead, New South Wales
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Affinity Clinical Research — Murdoch, Western Australia
- One Clinical Research Perth — Murdoch, Western Australia
- St John of God Hospital Subiaco — Subiaco, Western Australia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.